-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $230

Benzinga·11/16/2026 17:42:06
Listen to the news
Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and raises the price target from $221 to $230.